ストックスクリーナーアプリを入手
11.45
5.22%
-0.63
前日終値:
$12.08
開ける：
$12.07
24時間の取引高:
1.34M
Relative Volume:
0.77
時価総額：
$1.02B
収益：
$71.64M
当期純損益:
$-294.57M
株価収益率:
-3.42
EPS:
-3.348
ネットキャッシュフロー:
$-84.46M
1週間 パフォーマンス:
+3.15%
1か月 パフォーマンス:
+31.91%
6か月 パフォーマンス:
+21.68%
1年 パフォーマンス:
+80.03%
1日の値動き範囲:
$11.18
$12.10
1週間の範囲:
$10.71
$12.22
52週間の値動き範囲:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
名前
Kura Oncology Inc
セクター
電話
(858) 500-8800
住所
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
11.45 | 1.02B | 71.64M | -294.57M | -84.46M | -3.348 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | 開始されました | Lake Street | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Neutral |
| 2025-02-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-14 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-08-11 | 開始されました | BofA Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-05-17 | 開始されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2022-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 開始されました | Jefferies | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-11-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-11-09 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-13 | 再開されました | Leerink Partners | Outperform |
| 2016-01-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-30 | 開始されました | Oppenheimer | Outperform |
| 2015-12-16 | 開始されました | Citigroup | Buy |
すべてを表示
Kura Oncology Inc (KURA) 最新ニュース
(KURA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to sales forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Price to book forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win (NASDAQ:KURA) - Seeking Alpha
Does Kura Oncology’s (KURA) Shift Into Russell Growth Indexes Redefine Its Core Investment Story? - Yahoo Finance
Kura Oncology outlines targeted cancer pipeline as investors watch clinical milestones - ad-hoc-news.de
Kura Oncology (KURA) Gains Nearly 3% as Shares Test Key Resistance ZoneAnalyst Downgrade Signals - dars.gov.et
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Kura Oncology offers stock options to five new hires - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Kura Oncology reports $5.8 million revenue in Q1 2026 - scanx.trade
Kura Oncology, Inc.(NasdaqGS:KURA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2500 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) added to Russell 2000 Growth Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Kura Oncology, Inc.(NasdaqGS: KURA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Kura Oncology, Inc. Actuals & Estimates (NASDAQ:KURA) - TradingView
Kura Oncology, Inc. Actuals & Estimates (HAM:KUR) - TradingView
Kura Oncology, Inc. liabilities 2021-2025 - Statista
Kura Oncology, Inc. Actuals & Estimates (DUS:KUR) - TradingView
KURA Forecast — Price Target — Prediction for 2027 - TradingView
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Insiders At Kura Oncology Sold US$1.5m In Stock, Alluding To Potential Weakness - 富途牛牛
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock By Investing.com - Investing.com Australia
Form 4 Kura Oncology Inc For: 22 June By Investing.com - Investing.com India
Kura Oncology CMO Mollie Leoni sells $834,283 in common stock - Investing.com
Kura Oncology (NASDAQ: KURA) CMO sells 84,929 shares in trading plan - Stock Titan
Understanding the Setup: (KURA) and Scalable Risk - Stock Traders Daily
[144] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology Inc (KURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kura Oncology Inc (KURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kura Oncology Inc (KURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology Inc (KURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kura Oncology Inc (KURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kura Oncology Inc (KURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kura Oncology Inc (KURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
KURA: Ziftomenib demonstrates high remission rates and strong safety in AML, supporting global expansion - TradingView
Kura Oncology Inc (KURA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):